Modem therapy of acute lymphocytic leukaemia (ALL) in children attempts to achieve prolonged continuous remission. Effective use of multiple agent combination therapy for the control of systemic disease has increased the incidence and prolonged the duration of the survival of children with acute lymphoblastic leukaemia. Prolongation of survival is the chief cause for the increased incidence of central nervous system (CNS) leukaemia, and this has led to the realization of the importance of preventing CNS infiltration (Evans, Gilbert, and Zandstra, 1970) . For this reason, prophylactic cranial irradiation and intrathecal methotrexate (MTX) or craniospinal irradiation are being used routinely in the management of this Received 18 March 1975. disease. The results of these programmes in welldesigned controlled studies have been shown to be superior to chemotherapy alone (Aur et al., 1971 ; Aur et al., 1972; Holland and Glidewell, 1972 (Nies et al., 1965; Mathe et al., 1966; Sharp et al., 1967; Simone, Holland, and Johnson, 1972) . Early recurrence has been attributed to the persistence of extramedullary foci which was not eradicated by in- creasing the intensity of chemotherapy (Mathe et al., 1966) . These reports prompted us to add irradiation to the organs with the highest incidence of leukaemic infiltration, namely, the liver, spleen, and kidneys, to eradicate clinically occult foci of leukaemic cells in these organs. In addition to organ irradiation, prophylactic CNS therapy and combination chemotherapy, as described previously (Aur et al., 1971; Aur et al., 1972) , was administered. Materials and methods An outline of treatment is illustrated in Table II. Phase I (induction of remission). Remission was induced with the use of vincristine (VCR) 1-5 mgln2 intravenous weekly for 5 weeks and prednisone (Pred) 40 mg/m2 orally daily in two to three divided doses for (a) Organ irradiation (local therapy). Within one week of attaining remission, prophylactic therapy to the CNS was given to patients under 2 years of age as 1800 rads in 9 treatments, and to those over 2 years as 2400 rads in 12 treatments. The cranium was irradiated through opposing lateral ports using a cobalt-60 unit. In addition, methotrexate was adminstered intrathecally in doses of 12 mg/m2 twice weekly for 5 doses during cranial irradiation treatment. 4 of our early patients received irradiation to the entire craniospinal axis in doses of 2400 rads and received no intrathecal MTX.
A week after completion of prophylactic CNS therapy, the right part of the liver and right kidney were irradiated with a total dose of 1200 rads in 10 divided treatments through two opposing ports. 4 weeks thereafter the left part of the liver, the spleen, and left kidney were irradiated in the same manner. The spinal column was shielded during irradiation. (b) Continuation chemotherapy (systemic therapy). Continuation therapy with antileukaemic drugs given orally consisted of 6-mercaptopurine (6MP) 50 mg/M2 daily, methotrexate (MTX) 20 mg/M2 weekly, and cyclophosphamide (CPM) 200 mg/M2 weekly. 6MP was instituted as soon as bone marrow remission was achieved and prednisone was tapered. Oral MTX and CPM were instituted one week after the last dose of IT-MTX and were administered together weekly.
Pulsed doses of VCR 1 5 mg/rn2 weekly intravenously for 2 weeks and Pred 40 mg/m2 daily orally for 2 weeks were administered every 10-12 weeks. (Lanzkowsky and Shende, 1975a) . One female patient had absent right pectoral muscles in association with a large haemangioma on the left forearm (Lanzkowsky, 1975) . One patient had haemangioma in the cervical region. One female presented with a subcutaenous leukaemic nodule over the forehead.
Initial total white blood cell counts varied from 2100-204 000/mm3 2 1-204-0 x 109/1). No correlation was found between visceromegaly and the level of the white cell count (Lanzkowsky and Shende, 1975b The difference in survival rates between high and standard risk groups was significant, suggesting that this regimen is unsatisfactory in the treatment of high risk groups ( Fig. 1 and 2 (12)(9) (1) (6) (5) (4) (3) (2) (2) (2) (2) (1) ) ) (1) (1) Six patients developed excessive drowsiness, for periods of from 1 to 6 weeks, after cranial irradiation. One had fever intermittently for a 2-week period associated with drowsiness after irradiation. Alopecia of 3 to 4 months' duration was observed in all the patients after cranial irradiation. Linear growth retardation was observed in 3 out of the 4 patients who received spinal irradiation. One patient developed transient haematuria towards the end of irradiation therapy to the right kidney, and therefore irradiation to the left kidney and spleen was omitted. One patient, who had received L-asparaginase followed 4 weeks by irradiation to to the liver, developed abnormal liver function tests (SGOT, SPGT, and serum bilirubin) from 1 to 9 weeks after therapy.
Infectious complications. Induction phase. Fever (temperature > 39°C) was observed in 24 of the 30 patients during induction. 13 of these had fever of undetermined origin, 4 had documented septicaemia or fungaemia, 6 had bronchopneumonia, and 1 had suppurative lymphadenitis. Of the 4 with septicaemia or fungaemia, 2 had Esch. coli, 1 Pseudomonas, and 1 candidiasis.
Maintenance phase. 10 patients had pyrexia temperature > 39°C) ofundetermined origin during maintenance therapy. Individually they had from one to four episodes of pyrexia of undetermined origin. No patient had documented septicaemia or fungaemia during the maintenance phase. One patient developed signs of mild hepatotoxicity during irradiation after the use of Lasparaginase, and this should probably be avoided if hepatic irradiation is to follow its use.
Of the 3 patients in whom necropsies were performed, none had evidence of organ damage secondary to irradiation. All 3 patients had leukaemic infiltration of the bone marrow and spleen, 2 had infiltration of liver, lymph nodes, and brain, and 1 had infiltration of the kidney. 1 patient had extensive fungal abscesses in the liver and gastrointestinal tract. One of the patients developed laryngeal stridor during relapse and laryngeal leukaemic infiltrates were found at necropsy. This unusual finding has recently been described in a patient with acute myeloid leukaemia (Ti et al., 1974) .
In conclusion, the results of this investigation show that children with ALL who are in the high risk category with WBC counts >25 000/mm3 (25 x 109/1) should be identified and treated by a regimen other than the standard therapy in use today. 
